Castuner

Entzun zure aplikazioan

Atalak

191 atal

  1. Artificial Intelligence Advances Lymphoma Diagnosis, Biomarker Identification, and Precision Treatment 5:17
  2. Immune Checkpoint Inhibition in Advanced cSCC: Perspectives From Clinical Practice 10:57
  3. Immune Checkpoint Inhibition in Advanced cSCC: Perspectives From Clinical Practice 12:28
  4. Immune Checkpoint Inhibition in Advanced cSCC: Perspectives From Clinical Practice 13:58
  5. Preparing for Biomarker-Directed Care in epNEC: What Pathologists Need to Know Now 12:28
  6. Artificial Intelligence for Skin Cancer Diagnosis 11:57
  7. Beyond FVC: What FIBRONEER-ILD Means for Outcomes, Patients, and Access in PPF 17:10
  8. Real-World Decision Points in Biomarker-Driven NSCLC Management 5:17
  9. Connecting the Dots: How MET Fits Into Comprehensive Molecular Profiling 3:56
  10. Testing Matters: Practical Approaches to Biomarker Evaluation in NSCLC 6:47
  11. Tafasitamab Plus Lenalidomide Improves Frontline Outcomes in High-Risk Diffuse Large B-Cell Lymphoma 6:30
  12. When to Raise the Question of CAR T–Cell Therapy in Multiple Myeloma 8:50
  13. Closing the Gap Between CAR T–Cell Therapy Recognition and Referral in Multiple Myeloma 13:03
  14. Olverembatinib Plus Blinatumomab Produces Deep Responses in Ph+ Acute Lymphoblastic Leukemia 3:44
  15. How is ctDNA MRD Testing Used in Lymphoma Care? 9:11
  16. How Are We Detecting Residual Disease in Lymphoma Today? 8:48
  17. How Are We Detecting Residual Disease in Lymphoma Today? 8:59
  18. Treatment of Recurrent Refractory Pediatric Low-Grade Glioma (pLGG) 8:55
  19. Navigating The Complexity of Melanoma Care: Part 6 2:01
  20. Navigating The Complexity of Melanoma Care: Part 5 1:35
  21. Navigating The Complexity of Melanoma Care: Part 4 2:40
  22. Navigating The Complexity of Melanoma Care: Part 3 1:15
  23. Navigating The Complexity of Melanoma Care: Part 2 2:16
  24. Navigating The Complexity of Melanoma Care: Part 1 2:46
  25. Community Education Program Improves Patient Education and Cancer Screening Rates 7:01
  26. Cholangioscopy: What Interventional Oncologists Need to Know Part 2 46:05
  27. Cholangioscopy: What Interventional Oncologists Need to Know 41:01
  28. Applications of AR in Interventional Oncology 11:45
  29. How Artificial Intelligence May Change Interventional Oncology 26:30
  30. Sacituzumab Govitecan Plus Pembrolizumab in the TROPHY-U-01 Trial 7:31
  31. Episode 1: Maintenance Rituximab for Waldenström Macroglobulinemia 26:10
  32. Neoadjuvant Chemotherapy Plus HER2-Targeted Therapy for Early Stage HER2-Positive Breast Cancer 7:17
  33. Advances in Gastrointestinal Genetic Testing 4:51
  34. Enfortumab Vedotin for Metastatic Urothelial Cancer After Progression on Platinum-Based Chemotherapy 6:58
  35. BRCAness May Predict Response to Platinum-Based Chemotherapy in Intrahepatic Cholangiocarcinoma 7:33
  36. Durvalumab Conveys Benefit for All Biliary Tract Cancer Types 5:29
  37. Pemigatinib for Cholangiocarcinoma with FGFR2 Fusions or Rearrangements 4:32
  38. Maintenance Cabozantinib in Metastatic Urothelial Carcinoma 4:51
  39. Sacituzumab Govitecan Plus Pembrolizumab for Platinum-Refractory Metastatic Urothelial Cancer 8:45
  40. Part 2: Overcoming PARP Inhibitor and Platinum Resistance in Patients With Ovarian Cancer 7:06
  41. Part 1: Current Emerging Therapies for Platinum-Resistant Ovarian Malignancies With Dr O'Mally 9:48
  42. Therapeutic Advances and Considerations for Treatment Selection in High-Risk AML 25:00
  43. Ibrutinib Improves Outcomes Over Rituximab Among Patients With Advanced CLL/SLL 8:40
  44. Evolving Roles of KRAS Inhibitors in CRC 1:45
  45. The Role of Tumor Mutation Burden Featuring Dr Morris 0:50
  46. Dr Morris Discusses Emerging Targeted Therapies in mCRC 3:02
  47. Dr Lieu Talks ctDNA to Guide CRC Treatment 3:15
  48. Dr Casulo Overviews Approved Treatment Options to Manage Newly Diagnosed, Relapsed FL 5:20
  49. Dr Batlevi Shares Promising Data of Tazemetostat from SYMPHONY-1 Trial 4:46
  50. Dr Loprinzi Reviews Hot Flash Treatment Strategies in BC, Part II 0:19